TriangleNCT02393859 · OUTCOME
Number of Participants With Anti-Blinatumomab Antibodies Postbaseline (Blinatumomab Arm Only)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- participants
- Interval / dispersion
- Not reported
- Time frame
- Day 1 to Day 29.
What was measured
Participants receiving blinatumomab had blood samples analyzed for binding antibodies. Samples testing positive for binding antibodies were also tested for neutralizing antibodies. Participants who were binding antibody-positive or neutralizing antibody-positive post-baseline with a negative or no result at baseline are presented.
Analysis population: Safety Analysis Set: participants who received protocol-specified therapy analyzed according to the treatment they received. Participants in the blinatumumab arm with a post-baseline result.
Groups in this outcome
Blinatumomab
One 4-week cycle of blinatumomab 15 μg/m\^2/day as a continuous intravenous infusion (CIVI).
| Group | Source count |
|---|---|
| Blinatumomab | 52 |
Reported measurements
Binding Antibody Positive
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Blinatumomab | 0 | Not reported | Not reported | Not reported | Not reported |
Neutralizing Antibody Positive
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Blinatumomab | 0 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 0
- title
- Binding Antibody Positive
- categories
- measurements
- group Id
- OG000
- value
- 0
- title
- Neutralizing Antibody Positive
- denoms
- counts
- group Id
- OG000
- value
- 52
- units
- Participants
- description
- Participants receiving blinatumomab had blood samples analyzed for binding antibodies. Samples testing positive for binding antibodies were also tested for neutralizing antibodies. Participants who were binding antibody-positive or neutralizing antibody-positive post-baseline with a negative or no result at baseline are presented.
- groups
- description
- One 4-week cycle of blinatumomab 15 μg/m\^2/day as a continuous intravenous infusion (CIVI).
- id
- OG000
- title
- Blinatumomab
- param Type
- NUMBER
- population Description
- Safety Analysis Set: participants who received protocol-specified therapy analyzed according to the treatment they received. Participants in the blinatumumab arm with a post-baseline result.
- reporting Status
- POSTED
- time Frame
- Day 1 to Day 29.
- title
- Number of Participants With Anti-Blinatumomab Antibodies Postbaseline (Blinatumomab Arm Only)
- type
- SECONDARY
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice